EUCTR2006-005010-12-DE进行中（未招募）不适用
A multicenter, open-label, single-arm study to evaluate the single-dose pharmacokinetics, acceptability and safety of famciclovir oral pediatric formulation in infants 1 month to <1 year of age with herpes simplex or varicella zoster virus infections
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female patients from 1 month to <1 year of age, regardless of their immune status, who have active, suspected or latent herpes simplex infection, who are at risk of developing herpes simplex virus infections, and who are candidates for antiviral therapy.
- •2. Patients may be starting or currently using acyclovir. Patients on oral, i.v. or topical antiviral therapy (acyclovir, valacyclovir, ganciclovir) ideally should have a wash-out period of =8 hours prior to study drug administration. The investigator will carefully assess the impact of discontinuing standard therapy before enrollment. If the investigator feels that discontinuation of current antiviral is not indicated, then the patient may be enrolled without a washout period. Patients who require episodic antiviral treatment (acyclovir or valacyclovir) should be given their final dose =8 hours prior to dosing.
- •3. Patients expected to survive more than 4 weeks.
- •4. Patients whose physical examination demonstrates no abnormalities that would make this study medically hazardous to them.
- •5. Patients with Informed Consent Forms [approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)] signed by the parent/legal guardians
- •6. Patients whose parent/guardians are able to follow verbal and/or written instructions in the local language.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with a gestational age <32 weeks. Patients with a gestational age <35 weeks are excluded from Cohort 1 only.
- •2. Patients unable to swallow (patients who are unconscious/coma due to encephalitis, patients who have extensive gingivo-stomatitis are excluded only if drinking is impaired)
- •3. Patients with a history of malabsorption or previous gastrointestinal surgery, or history of radiation therapy that could effect drug absorption or metabolism, or any other disorder or history of a condition that could interfere with drug absorption, distribution, metabolism, or excretion.
- •4. Patients with a clinically significant abnormality of the hepatic and renal systems.
- •5. Patients with any of the following age-adjusted clinical or hematological laboratory and blood chemistry abnormalities (Grade 2 abnormalities as defined by ranges of the local laboratory. The following values are given as guidances):
- •- AST/SGOT or ALT/SGPT greater than 3x ULN
- •- Total bilirubin greater than 2x ULN
- •- Serum creatinine greater than 2x ULN
- •- Absolute WBC count less than 4000 /mm3
- •- Platelet counts less than 50 000 /mm.
- •- Hemoglobin < 7.0 g/dL
- •6. Patients with a known hypersensitivity to famciclovir or penciclovir or drugs with similar chemical structures.
- •7. Patients concomitantly using probenecid
- •8. Patients who sustained a significant blood volume loss (>3% of calculated blood volume) in the past 30 days.
- •9. Patients who have taken an investigational drug or participated in an investigational study (with the exceptions of protocols studying marketed nucleoside analogues for herpes infections) within 30 days or 5 half-lives (which ever is longer) prior to study drug administration.
研究者
相似试验
进行中（未招募）
1 期
A study to test the pharmacokinetics, efficacy, and safety of brivaracetam in newborns with repeated electroencephalographic seizures.Electroencephalographic neonatal seizuresEUCTR2015-002756-27-IECB Biopharma SPR42
招募中
2 期
Pharmacokinetics, safety, tolerability and efficacy of a new artemether-lumefantrine dispersible tablet in infants and neonates <5 kg body weight with acute uncomplicated Plasmodium falciparum malaria.PaediatricsMalariaPACTR202004535453508ovartis Pharma AG44
进行中（未招募）
1 期
A study to test the pharmacokinetics, efficacy, and safety of brivaracetam in newborns with repeated electroencephalographic seizures.EUCTR2015-002756-27-CZCB Biopharma SR42
进行中（未招募）
1 期
A study to test the pharmacokinetics, efficacy, and safety of brivaracetam in newborns with repeated electroencephalographic seizuresEUCTR2015-002756-27-BECB Biopharma SR42
进行中（未招募）
1 期
A study to test the pharmacokinetics, efficacy, and safety of brivaracetam in newborns with repeated electroencephalographic seizures.Electroencephalographic neonatal seizuresEUCTR2015-002756-27-GBCB Biopharma SPR42